CRISPR is the most powerful tool to edit genes with in history, allowing for miraculous or devastating results depending on how it is used. An anti-CRISPR tool was already found before, which prevents the method from making any unwanted mutations. Now, scientists have found an actual off switch so that the tool can be rendered useless.
The switch was found by researchers at the University of California, San Francisco within particular bacterial viruses, Phys.org reports. The new discovery has staggering implications on genetics and advanced medical technology since it allows scientists to have significantly more control over the powerful tool than before.
The study was led by Benjamin Rauch, the first author and Joseph Bondy-Denomy, the senior author. The results were published in a paper in the journal Cell.
The source of the switch is the Listeria monocytogenes, where up to four proteins that can make CRISPR ineffective were found. What’s more interesting is the fact that the CRISPR system that the proteins target is the Streptococcus pyogenes, which is the one that most researchers use. This makes the anti-CRISPR discovery a more all-encompassing solution to a serious problem in gene editing, Genome Web reports.
"Just as CRISPR technology was developed from the natural anti-viral defense systems in bacteria, we can also take advantage of the anti-CRISPR proteins that viruses have sculpted to get around those bacterial defenses," Rauch explained.
As to what effects and benefits this new tool could have, the answer has to do with some of the unintended consequences of an editing tool that can have a large area of effect. By adding the new anti-CRISPR system into the editing treatments that researchers use, it’s basically like creating a narrower, sharper scalpel for surgery. This leads to fewer risks of unnecessary cuts and allows for more expedient gene editing.


Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements
Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand
Dell Raises 2027 Revenue Forecast as AI Server Demand Drives Record Quarterly Results
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO
Huawei Chip Breakthrough Sparks Rally in Chinese Semiconductor Stocks
SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 



